Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis
- PMID: 21839112
- DOI: 10.1016/j.jinf.2011.07.016
Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis
Abstract
Urokinase plasminogen activator (uPAR) is a receptor mainly expressed on peripheral blood mononuclear cells and neutrophils. The role of its soluble form, namely suPAR, as a predictor of sepsis outcome in a homogenous cohort of 180 septic patients, was investigated. Blood from 180 patients with ventilator-associated pneumonia (VAP) and sepsis was collected for seven consecutive days. suPAR and PCT were measured in serum by an enzyme immunoassay and an immuno-time-resolved amplified cryptate assay respectively. Neutrophils and monocytes were isolated on day 1 and incubated. suPAR levels greater than 10.5 ng/ml had 80% specificity and 77.6% positive predictive value to discriminate between severe sepsis and sepsis. suPAR levels greater than 12.9 ng/ml had 80% specificity and 76.1% positive predictive value for prognosis of unfavorable outcome. suPAR levels were significantly lower among survivors than among non-survivors over follow-up. Step-wise Cox regression analysis found suPAR as an independent factor related with unfavorable outcome (p: 0.026). Concentrations of suPAR in supernatants of neutrophils of patients with sepsis were greater compared to controls. It is concluded that suPAR is a reliable marker of sepsis severity and a strong independent predictor of unfavorable outcome in VAP and sepsis. Neutrophils are involved in release.
Copyright © 2011 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Comment in
-
SuPAR in pleural fluid may function as a biological marker for infection in critically ill patients with pleural effusions.J Infect. 2014 Jun;68(6):607-9. doi: 10.1016/j.jinf.2014.02.005. Epub 2014 Feb 15. J Infect. 2014. PMID: 24534606 No abstract available.
Similar articles
-
Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis.Am J Emerg Med. 2016 Mar;34(3):375-80. doi: 10.1016/j.ajem.2015.11.004. Epub 2015 Nov 9. Am J Emerg Med. 2016. PMID: 26615223
-
Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study.J Intern Med. 2012 Sep;272(3):247-56. doi: 10.1111/j.1365-2796.2012.02569.x. Epub 2012 Jul 29. J Intern Med. 2012. PMID: 22755554
-
Could soluble urokinase plasminogen receptor (suPAR) be used as a diagnostic biomarker for ventilator-associated pneumonia?Clin Respir J. 2017 Nov;11(6):925-930. doi: 10.1111/crj.12438. Epub 2016 Feb 9. Clin Respir J. 2017. PMID: 26683264
-
suPAR as a prognostic biomarker in sepsis.BMC Med. 2012 Jan 5;10:2. doi: 10.1186/1741-7015-10-2. BMC Med. 2012. PMID: 22221662 Free PMC article. Review.
-
Serum soluble urokinase-type plasminogen activator receptor as a biological marker of bacterial infection in adults: a systematic review and meta-analysis.Sci Rep. 2016 Dec 19;6:39481. doi: 10.1038/srep39481. Sci Rep. 2016. PMID: 27991579 Free PMC article. Review.
Cited by
-
Angiopoietin2 is associated with coagulation activation and tissue factor expression in extracellular vesicles in COVID-19.Front Med (Lausanne). 2024 May 13;11:1367544. doi: 10.3389/fmed.2024.1367544. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38803346 Free PMC article.
-
qSOFA combined with suPAR for early risk detection and guidance of antibiotic treatment in the emergency department: a randomized controlled trial.Crit Care. 2024 Feb 6;28(1):42. doi: 10.1186/s13054-024-04825-2. Crit Care. 2024. PMID: 38321472 Free PMC article. Clinical Trial.
-
The accuracy of soluble urokinase-type plasminogen activator receptor for the diagnosis of neonatal sepsis: a meta-analysis.Front Med (Lausanne). 2023 Apr 27;10:1169114. doi: 10.3389/fmed.2023.1169114. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37181361 Free PMC article. Review.
-
Soluble Urokinase Plasminogen Activator Receptor (suPAR) in Autoimmune Rheumatic and Non Rheumatic Diseases.J Pers Med. 2023 Apr 19;13(4):688. doi: 10.3390/jpm13040688. J Pers Med. 2023. PMID: 37109074 Free PMC article. Review.
-
Biomarkers as Prognostic Predictors and Therapeutic Guide in Critically Ill Patients: Clinical Evidence.J Pers Med. 2023 Feb 15;13(2):333. doi: 10.3390/jpm13020333. J Pers Med. 2023. PMID: 36836567 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical